Thoma Bravo Announces Strategic Growth Investment In Bluesight To Support The Company'S Acquisition Of Medacist
Thoma Bravo Announces Strategic Growth Investment In Bluesight To Support The Company'S Acquisition Of Medacist
07/17/23, 1:02 PM
Industry
financial services
machine learning
artificial intelligence
biotechnology
health care
analytics
Thoma Bravo, a leading software investment firm, today announced the closing of a strategic growth investment in Bluesight, the Medication IntelligenceTM Company. The investment is expected to further enhance Bluesight's drug diversion prevention offerings through its acquisition of Medacist, a pioneer in drug diversion monitoring, and continue to grow Bluesight's inventory management and spend optimization offerings. Current investor New Leaf Ventures will remain invested in the business. Financial terms of the transaction were not disclosed.
Company Info
Company info
Thoma Bravo is one of the largest private equity firms in the world, with more than $83 billion in assets under management as of June 30, 2021. The firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging the firm’s deep sector expertise and proven strategic and operational capabilities, Thoma Bravo collaborates with its portfolio companies to implement operating best practices, drive growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings. Over the past 20 years, the firm has acquired more than 325 companies representing over $100 billion in enterprise value. The firm has offices in Chicago, Miami and San Francisco. For more information, visit thomabravo.com.